Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 121.00 | |
5 mg | In stock | $ 313.00 | |
10 mg | In stock | $ 513.00 | |
25 mg | In stock | $ 837.00 | |
50 mg | In stock | $ 1,160.00 | |
100 mg | In stock | $ 1,560.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 397.00 |
Description | Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection. |
In vivo | Linvencorvir (RO7049389) (600/1000 mg; oral; Caucasian and Asian, male and female) followed by 100 μg intravenous [13 C]RO7049389. The model performance in predicting the pharmacokinetic profiles of RO7049389 aligned with clinical observations in Caucasians and was also successfully applied to Asians. Accordingly, the drug disposition pathways for RO7049389 were postulated with newly characterized estimates of the fractions: biliary excretion by P-glycoprotein (~41%), direct glucuronidation via uridine 5'-diphosphoglucuronosyltransferase 1A3 (~11%), hexose conjugation (~6%), oxidation by CYP3A4 (~28%) and other oxidation reactions (~9%). These results support the ongoing clinical development program for RO7049389 and highlight the broader value of PBPK and MB analyses in drug development.[3] |
Synonyms | RG7907 |
Molecular Weight | 598.69 |
Formula | C29H35FN6O5S |
CAS No. | 1808248-05-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 56.2 mg/mL (94.0 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linvencorvir 1808248-05-6 Microbiology/Virology Antibiotic HBV RG7907 RG-7907 RG 7907 inhibitor inhibit